Your session is about to expire
← Back to Search
JNJ-77242113 for Plaque Psoriasis(SUMMIT Trial)
SUMMIT Trial Summary
This trial will test if a new oral tablet can effectively treat moderate to severe plaque psoriasis when compared to placebo.
- Plaque Psoriasis
SUMMIT Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
SUMMIT Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
SUMMIT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any prerequisites for participation in this research project?
"This medical trial is searching for 80 volunteers who are aged between 18 and 75, have had plaque psoriasis (psoriasis vulgaris) for at least 26 weeks prior to receiving the treatment, exhibit a total Body Surface Area of 10% or higher, display an Investigator's Global Assessment greater than 3 points, and present with a Psoriasis Area Severity Index of 12 points or above. Candidates must also be eligible for phototherapy or systemic therapy."
What kind of geographic scope does the research on this topic encompass?
"ActivMed Practices & Research in Portsmouth, New Hampshire; The Pennsylvania Centre for Dermatology, LLC in Exton, Pennsylvania; and Northshore Universite Healthsystem in Skokie, Illinois are three of the fifteen medical sites participating in this trial. An additional 12 locations are also offering treatment options."
Is the minimum age requirement for this research investigation over twenty years of age?
"Candidates aged between 18 and 75 are eligible for this trial. Additionally, there are 31 studies open to those under the age of 18, as well as 142 trials available for those over 65 years old."
Are recruitment efforts underway for this study?
"Affirmative. The clinicaltrials.gov listing confirms that this investigation is actively searching for participants, with the original posting taking place on June 13th 2022 and a recent update occurring on November 22nd 2022. This trial requires 80 people to be recruited from 12 different medical sites."
Has JNJ-77242113 been certified by the FDA?
"Taking into account the Phase 2 status of JNJ-77242113, our experts have assigned this medication a safety rating of 2. Although some data exists that prove its safety, there is still no evidence to support efficacy."
Approximately how many individuals have enrolled in this experiment?
"This trial seeks 80 volunteers who are eligible for participation. They can join the clinical study at ActivMed Practices & Research in Portsmouth, New Hampshire or The Pennsylvania Centre for Dermatology, LLC in Exton, Pennsylvania."
Share this study with friends